Application of miR-221-3p in preparation of external medicine for treating androgenetic alopecia and medicine composition for treating androgenetic alopecia

By wrapping miR-221-3p in the cell membrane and using microneedle introduction technology to activate the Wnt/β-catenin signaling pathway, the problem of poor stability of nucleic acid drugs in the body is solved, and effective treatment of androgenic hair loss is achieved. Significantly promotes hair growth.

CN118903182APending Publication Date: 2024-11-08WEST CHINA HOSPITAL SICHUAN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411259199.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-09
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing methods for treating androgenic hair loss have not yet been effectively utilized, and nucleic acid drugs have poor stability in the body and are difficult to play a role across the cell membrane.

Method used

MiR-221-3p is modified by 20-OMe phosphoramidite and wrapped in cell membranes. It is introduced through the skin using microneedle introduction technology, activates the Wnt/β-catenin signaling pathway, and regulates the hair follicle growth cycle.

Benefits of technology

It significantly promoted the dorsal hair growth of AGA model mice, improved the stability of miR-221-3p and its ability to cross the cell membrane, reduced its immunogenicity and cytotoxicity, and achieved the exact therapeutic effect of the treatment of androgenic hair loss.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903182A_ABST
    Figure CN118903182A_ABST
Patent Text Reader

Abstract

The invention provides an application of miR-221-3p (micro Ribonucleic Acid-221-3p) in preparation of an external medicine for treating androgenetic alopecia. The invention also provides a pharmaceutical composition for treating androgenetic alopecia, wherein the pharmaceutical composition is a preparation prepared from miR-221-3p wrapped by a cell membrane or miR-221-3p modified by 20-OMe phosphoramidite. The invention also provides a preparation method and application of the pharmaceutical composition. According to the invention, miR-221-3p is applied to local treatment of alopecia for the first time, and an exact curative effect is achieved; the stability and cell membrane crossing capacity of miRNA are improved by combining chemical modification and the cell membrane carrier, the immunogenicity and cytotoxicity of miRNA are reduced, and the miRNA can also be applied to development of other nucleic acid drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to use of miR-221-3p in preparing an external medicine for treating androgenic alopecia, and a pharmaceutical composition for treating androgenic alopecia. Background Art

[0002] The activity of type II 5α-reductase is enhanced in the main hair loss areas of the forehead and top of the head of AGA patients, which increases the content of dihydrotestosterone (DHT) converted from low-activity testosterone to high-activity. DHT binds to the androgen receptor (AR) in the dermal papilla (DP), leading to the dysregulation of multiple signaling pathways in the hair follicle growth cycle, shortening the growth phase and prolonging the resting phase, which transforms larger terminal hair fibers into smaller vellus hair fibers, known as hair follicle miniaturization. As more hair follicles are miniaturized, the hair coverage of the scalp gradually decreases, and eventually the ability to regenerate hair is lost. The signaling pathways that are dysregulated in the hair follicles of AGA patients mainly include Wnt / β-catenin, BMP, SHH, TGF, etc. Among them, Wnt / β-catenin is the most important signaling pathway that mediates the entry of hair follicles into the growth phase. Therefore, activating the Wnt / β-catenin signaling pathway in dermal papilla cells is the key to restoring the normal hair follicle cycle, reversing hair follicle miniaturization, and promoting hair growth.

[0003] miR-221-3p is a microRNA (miRNA) that plays an important regulatory role in cells. miRNA is a class of endogenous small non-coding RNA molecules that participate in a variety of biological processes, including cell proliferation, differentiation, apoptosis, and immune response, by regulating gene expression at the post-transcriptional level. miR-221-3p regulates the expression of specific genes by complementary pairing with the 3' untranslated region (3'UTR) of the target mRNA. In the study of liver fibrosis, miR-221-3p was found to play an important role in the occurrence and development of liver fibrosis. Studies have shown that blocking the function of miR-221-3p in hepatocytes can promote the recovery of the liver and the faster elimination of deposited extracellular matrix, thereby alleviating the progression of liver fibrosis to a certain extent. This suggests that miR-221-3p may be a potential target for the treatment of liver fibrosis. In the study of liver fibrosis, miR-221-3p was found to play an important role in the occurrence and development of liver fibrosis. Studies have shown that blocking the function of miR-221-3p in hepatocytes can promote liver recovery and faster elimination of deposited extracellular matrix, thereby alleviating the progression of liver fibrosis to a certain extent. This suggests that miR-221-3p may be a potential target for the treatment of liver fibrosis. In addition, miR-221-3p also plays a role in cardiovascular disease. For example, in the study of heart failure, miR-221-3p was found to inhibit angiogenesis by targeting Hif-1α, thereby affecting the development of heart failure. In terms of immune response, miR-221-3p can drive the transition of M2 macrophages to pro-inflammatory function by inhibiting the activation of the JAK3 / STAT3 signaling pathway.

[0004] There is currently no report on the use of miR-221-3p in the treatment of androgenic alopecia. Summary of the invention

[0005] The present invention finds that miR-221-3p has the effect of promoting hair growth by down-regulating the transcriptional expression of DKK2, an upstream inhibitory protein of the Wnt / β-catenin pathway, and activating the Wnt / β-catenin signaling pathway. The present invention provides a new use of miR-221-3p.

[0006] The present invention provides use of miR-221-3p in preparing an external medicine for treating androgenic alopecia.

[0007] Wherein, the drug is a drug used to regulate the growth cycle of hair follicles.

[0008] Wherein, the medicine is a medicine for improving the hair growth phase.

[0009] The present invention provides a pharmaceutical composition for treating androgenic alopecia, which is a preparation prepared by encapsulating miR-221-3p with cell membrane or miR-221-3p modified with 20-OMe phosphoramidite.

[0010] Wherein, the preparation is rolling needle, subcutaneous injection, microneedle.

[0011] Among them, the cell membrane is derived from the skin precursor cell extract described in Patent No. ZL202010192592.7.

[0012] Wherein, the cell membrane extraction method comprises the following steps:

[0013] After culturing human skin precursor cells to 80% confluence, the culture medium was poured out, washed with PBS, and the cell pellet was collected;

[0014] Add membrane extract solution for lysis, shake at 4°C, and after the cells are broken, centrifuge at 700 rpm for 10 minutes to take the supernatant, and centrifuge at 12000 rpm for 50 minutes to collect the precipitate to obtain the cell membrane (CM).

[0015] The present invention provides a method for preparing the pharmaceutical composition for treating androgenic alopecia, which is prepared by the following steps:

[0016] a. Extract cell membrane and prepare suspension;

[0017] b. preparing a suspension of miR-221-3p or miR-221-3p modified with 20-OMe phosphoramidite;

[0018] c. The cell membrane suspension is mixed with the suspension of miR-221-3p-mimic to prepare liposomes, which are self-assembled into a cell membrane-wrapped structure, and then pharmaceutically acceptable excipients or auxiliary ingredients are added to prepare a commonly used external preparation.

[0019] Wherein, the cell membrane suspension described in step a is prepared into a suspension with a concentration of 0.2 mg / ml using sterile RNase-free-PBS;

[0020] The concentration of the miR-221-3P solution in step b is 20uM;

[0021] The volume ratio of cell membrane suspension to cell membrane suspension was 1:8.

[0022] The present invention applies miR-221-3p to the treatment of AGA model mice for the first time and achieves good therapeutic effect; nucleic acid drugs have poor stability in the body, are easily degraded by nucleases, and are difficult to cross the cell membrane to exert their effects. The present invention chemically modifies miR-221-3p and adds cell membrane (CM) for wrapping, which well overcomes the above technical difficulties. The miR-221-3p-mimic-CM is introduced through the skin for administration using microneedle introduction technology. Studies have found that miR-221-3p-mimic-CM can promote the growth of back hair in AGA model mice. Further studies have found that miR-221-3p-mimic-CM regulates the hair follicle growth cycle by activating the Wnt / β-catenin signaling pathway in AGA model mice.

[0023] The cell membrane used in the present invention is that the human skin precursor cells are neural crest-derived stem cells. The neural crest-derived cell population in the skin includes cells from the bulge area to the matrix at the bottom of the hair follicle in the outer root sheath of the hair follicle. This expression cell membrane is more easily absorbed by the hair follicle.

[0024] The present invention applies miR-221-3p to the local treatment of hair loss for the first time and achieves a definite therapeutic effect. The present invention combines chemical modification and cell membrane carriers to increase the stability of miRNA and its ability to cross the cell membrane, and reduces its immunogenicity and cytotoxicity, and can also be used in the development of other nucleic acid drugs. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1 Before cell membrane wrapping;

[0026] Figure 2 After cell membrane wrapping;

[0027] Figure 3 Schematic diagram of the binding of miR-221-3p to h-DKK2-3UTR target;

[0028] Figure 4 Interaction of miR-221-3p with h-DKK2-3UTR;

[0029] Figure 5 miR-221-3p is taken up by dermal papilla cells;

[0030] Figure 6 Proliferation rate of human DPCs cells after treatment with miR-221-3p-mimic-CM;

[0031] Figure 7 Effects of miR-221-3p-mimic-CM on the migration ability of DPCs;

[0032] Figure 8Effects of treatment groups on upstream target proteins and downstream related proteins of the Wnt pathway in human DPCs;

[0033] Fig. 9 Mouse gross figure;

[0034] Fig.10 Mouse dermoscopy images;

[0035] Fig.11 HE staining images of different treatment groups (scale bar = 10 μm);

[0036] Fig.12 Immunohistochemistry of DKK2 in different treatment groups;

[0037] Fig.13 β-catenin immunohistochemistry in different treatment groups;

[0038] Fig.14 Immunohistochemistry of LEF1 in different treatment groups;

[0039] Fig.15 C-myc immunohistochemistry images of different treatment groups;

[0040] Fig.16 Immunohistochemistry of CyclinD1 in different treatment groups;

[0041] Fig.17 Trends in immunohistochemically positive cell fractions in different treatment groups. DETAILED DESCRIPTION

[0042] Example 1 Preparation of microneedles of the present invention

[0043] 1. Synthesis of miR-221-3p-mimic:

[0044] The sequence of miR-221-3p is: 5'-AGC UAC AUU GUC UGC UGG GUU UC-3'

[0045] Synthesize miR-221-3p-mimic using solid phase phosphoramidite chemistry using an automated DNA / RNA synthesizer:

[0046] ① Set the parameters according to the DNA / RNA synthesizer guide, including synthesis scale, synthesis sequence, protecting group (5'-O-dimethoxytriphenyl (DMT)), insertion position of 20-OMe phosphoramidite (non-seed region), coupling time (50 s), oxidation time (50 s), and deprotection time (60 s).

[0047] ② Use controlled pore glass (CPG) as a solid support to install it into the synthesizer and start the synthesis process;

[0048] ③ Loading protected nucleotides: Load protected nucleotides (with 5'-O-dimethoxytriphenyl (DMT) protecting group) into the synthesis column.

[0049] ④ The synthesizer gradually adds each phosphoramidite monomer according to the designed miRNA sequence. The synthesis process includes: deprotection, activation, coupling, and repeated synthesis steps to gradually construct the RNA sequence.

[0050] ⑤ Deprotection and completion of synthesis: After the last nucleotide is coupled, use AMA solution to remove all protecting groups.

[0051] ⑥Purification: Purify the synthesized RNA by centrifugal filtration.

[0052] ⑦Quality control: Use UV spectrophotometer to measure RNA concentration, and use gel electrophoresis to confirm RNA length and purity;

[0053] The MiRNA mimic used in this application is a small double-stranded miRNA designed and synthesized for the mature form of miRNA. It has the same function as the mature form of miRNA and can upregulate the content of the corresponding miRNA in the cell. MiRNA inhibitor is a chemically modified inhibitor specifically targeting specific target miRNA in the cell. It can competitively bind to the mature miRNA sequence, weaken the gene silencing effect of endogenous miRNA, and increase the expression of downstream proteins. Both MiRNA mimic and miRNA inhibitor can be synthesized by synthesis companies and are easy to obtain.

[0054] 2. Construct cell membrane (CM) vector and load miR-221-3p-mimic

[0055] ① Extraction of cell membrane: Culture transformed human skin precursor cells (patent number ZL202010192592.7) in a 10 cm culture dish until the cell growth and fusion reaches about 80%. Pour the culture medium, wash once with PBS, remove the culture medium residue, and collect the cell precipitate. Add 5 mL of membrane extract (the volume ratio of membrane protein extract A to PMSF is 100:1) to the precipitate (the membrane protein extract A is a commercially available product, purchased from: Beyotime Biotechnology-Cell Membrane Protein and Cytoplasm Protein Extraction Kit (P0033) Membrane Protein Extraction Reagent A https: / / www.beyotime.com / product / P0033.htm) to perform cell lysis. The membrane extract is prepared and used immediately, and the addition time is controlled within 1 minute; place at 4°C for 25 minutes, and shake once every 3 minutes to ensure sufficient lysis. Grind the lysed cells in a tissue homogenizer to ensure that the cells are completely broken; centrifuge the cell fragments at 700rpm for 10 minutes, and take the supernatant. The supernatant was centrifuged again at 12000 rpm for 50 minutes, the supernatant was discarded, and the precipitate was collected. This precipitate is the cell membrane (CM).

[0056] ② Preparation of cell membrane-encapsulated miR-221-3p-mimic: The cell membrane suspension and the miR-221-3p-mimic suspension were mixed at a ratio of 1:8 (UV-Vis spectroscopy semi-quantitative), and allowed to stand for 1 hour to allow them to approach each other. Then, a microliposome extruder (Aventi) was used to repeatedly extrude the mixture using filter membranes of different pore sizes (1000 nm, 400 nm, 200 nm, Nuclepore, Track-etchMembrane, Cytiva), and repeated 30 times to allow them to self-assemble into a cell membrane-encapsulated structure (see Figure 1 , Figure 2 ).

[0057] The self-assembled structure of miR-221-3p-mimic wrapped by cell membrane is prepared into a rolling needle. The rolling needle, also known as a microneedle roller, is a skin microneedle treatment tool. It is improved based on the principle of plum blossom needle and consists of a syringe and a needle handle. Short needles arranged equidistantly are fixed on the syringe. According to different treatment needs, the rolling needle can choose short needles of different lengths and diameters. It can also be prepared according to the methods reported in the literature, such as: Yang Yutong, et al., Research Progress on the Application of Microneedles in Facial Rejuvenation Treatment, Chinese Journal of Aesthetic Medicine, Vol. 32, No. 10, October 2023.

[0058] The beneficial effects of the present invention are demonstrated by in vitro tests and efficacy tests.

[0059] Experimental Example 1 Prediction and identification of miR-221-3p target genes

[0060] ① Targetscan database analysis showed that the possible target gene of miR-221-3p in the Wnt pathway is DKK2 transcription mRNA. DKK2 is a negative regulatory protein upstream of the Wnt pathway; base pairing analysis found that miR-221-3p can bind to 6 base pairs at one site of DKK2 transcription mRNA ( Figure 3 ), thereby interfering with the translation of mRNA and downregulating the expression of DKK2 protein.

[0061] ② The dual luciferase reporter assay showed that compared with the mimic-NC group, mimic significantly downregulated the expression of h-DKK2-3UTR-wt luciferase (* represents P < 0.001), indicating that the two were mutually associated in this experiment, suggesting that DKK2 is the target of miR-221-3p in regulating the Wnt / β-catenin signaling pathway (see Figure 4 ).

[0062] Experimental Example 2 Effect of miR-221-3p-mimic-CM on Dermal Papilla Cells (DPCs)

[0063] ① Uptake of miR-221-3p-mimic-CM by DPCs: DPCs within three generations were taken and inoculated in a 24-well plate at 2.5×104 / mL. The cells were grown in the 24-well plate for 24 hours. The cell confluence was 30-50% during transfection. The original culture medium in the cell culture dish was discarded, 500μL complete culture medium was added to each well, miR-221-3p-mimic-CM was added to the culture dish at 100μL / well, and the cell plate was gently shaken in the "one" method to mix, and then cultured in a 37°C, 5% CO2 incubator; after 72 hours, the transfection efficiency was observed by fluorescence microscopy. (See Figure 5 ).

[0064] ②Effects of miR-221-3p-mimic-CM on the proliferation rate and migration ability of DPCs:

[0065] Proliferation rate: We added miR-221-3p-mimic-CM (mimic group), miR-221-3p-inhibitor-CM (inhibitor group), the corresponding blank controls mimic-CM-Nc (mimic-NC group), inhibitor-CM-Nc (inhibitor-NC group), and the positive control minoxidil (minoxidil group) into the culture medium of DPCs, and detected the cell proliferation rate of DPCs using CCK8 kit after 24, 48 and 72 hours of treatment ( Figure 6). At 24 hours, there was no significant difference in the cell proliferation rate of DPCs in each treatment group (P>0.05). At 48 hours, the proliferation rate of DPCs in the mimic group was significantly higher than that in the inhibitor group and the blank control group, and the difference was statistically significant (P<0.05); it was slightly lower than that in the minoxidil group, and the difference was not statistically significant (P>0.05); at 72 hours, the cell proliferation rate in the mimic group continued to increase, but the upward trend slowed down, and the cell proliferation rate was higher than that in the inhibitor group and the blank control group, and the difference was statistically significant (P<0.05); the cell proliferation rate in the minoxidil group decreased compared with that at 48 hours, lower than the mimic group, but still higher than the mimic-Nc group, and the difference was statistically significant (P<0.05).

[0066] Migration ability: We used the scratch test to detect the migration ability of DPCs after intervention. The results showed that the cell gaps in the mimic group were basically closed after 48 hours, indicating that miR-221-3p-mimic-CM has a significant promoting effect on the migration ability of DPCs ( Figure 7 ).

[0067] ③ Effect of miR-221-3p on the Wnt / β-catenin signaling pathway in DPCs: Western blot was used to detect protein expression in DPCs after intervention, such as Figure 8 As shown: When DPCs are

[0068] After 72 hours of intervention with miR-221-3p-mimic-CM / inhibitor-CM, minoxidil, etc., Western blot was used to detect the expression of DKK2, an upstream negative regulatory protein of the Wnt / β-catenin pathway, and downstream related proteins β-catenin, LEF1, C-myc, and CyclinD1. It was found that the expression of DKK2 was significantly downregulated in the mimic group, and the difference was statistically significant compared with the other groups (P<0.05); the expression of β-catenin and LEF1 in the mimic group was significantly higher than that in the inhibitor group, Minoxidil group, and blank control group, and the difference was statistically significant (P<0.05). The expression of C-myc and CyclinD1 in the mimic group was slightly higher than that in the blank and inhibitor groups, and the difference was not statistically significant. This indicates that miR-221-3p-mimic may activate the Wnt / β-catenin pathway by downregulating DKK2 in DPCs cultured in vitro, thereby upregulating the expression of β-catenin and LEF1.

[0069] Experimental Example 3 Effect of miR-221-3p-mimic-CM on the dorsal hair of AGA model mice

[0070] ① The AGA model mice were randomly divided into five groups: mimic group, inhibitor group, mimic-NC group, inhibitor-NC group, and minoxidil group. After intervention, the skin of different treatment groups showed different degrees of darkening around the 14th day. In the mimic group and minoxidil group, obvious darkening areas of skin and a small amount of hair growing out of the skin were observed, while the other groups were light gray. On the 21st day, the back skin color of each group further deepened. The inhibitor group, mimic-NC group, and inhibitor-NC group showed small areas of flaky black skin and a small amount of hair growing out of the skin. The mimic group and minoxidil group showed large areas of black skin with more hair growing out of the skin. On the 28th day, all groups had a large amount of dorsal hair growing out of the skin, but the dorsal hair coverage area of ​​the mimic group and minoxidil group was significantly larger than that of the inhibitor group, mimic-NC group, and inhibitor-NC group. There was no significant difference in the trend of skin color change and dorsal hair growth between the mimic group and the minoxidil group under the naked eye (see Fig. 9 ).

[0071] Dermoscopic findings Fig.10 On the 7th day, light gray changes appeared on the backs of mice in the mimic and minoxidil groups, which were more obvious in the minoxidil group, while the backs of mice in the other groups were pink, indicating that the growth period of the mimic and minoxidil groups was earlier than that of the other groups; on the 14th day, all groups were observed to have varying degrees of gray pigmentation, but the skin color of the mimic and minoxidil groups was darker, and a small amount of new hair shafts grew out of the skin; on the 21st day, the pigmentation of the back skin of mice in each treatment group was more obvious, and new hair grew, and the new hair in the mimic and minoxidil groups was denser.

[0072] ② Mouse tissue pathological staining and results

[0073] The results of HE staining of mice at different time periods are shown in Fig.11 On the first day, the number of hair follicles in all treatment groups was small, and the hair follicles were shallow, located in the deep dermis, and did not reach the subcutaneous fat layer. On the 7th day, a small number of hair follicles in the mimic group and the minoxidil group reached the subcutaneous fat layer, but the number of hair follicles in all groups was still small. On the 14th day, the number of hair follicles in the mimic group and the minoxidil group increased significantly, and more hair follicles reached the subcutaneous fat layer; on the 21st day, the hair follicles in each group reached the fat layer, but the mimic group and the minoxidil group were still significantly more than the other groups.

[0074] ③Immunohistochemistry and results

[0075] We performed immunohistochemistry on the skin tissues of mice in different treatment groups and at different time periods to detect the expression of Wnt pathway-related proteins DKK2, β-catenin, LEF1, C-myc, and CyclinD1. The results are as follows:

[0076] DKK2: All groups showed positive expression on hair follicles; over time, each treatment group showed different degrees of downregulation, among which the Mimic group showed the most obvious downregulation, and the expression level was significantly lower than that of the other groups ( Fig.12 , Fig.17 A.);

[0077] β-catenin: The epidermis and outer root sheath cells of hair follicles in different treatment groups were weakly expressed on the 7th day; as time went on, the expression level of β-catenin in the Mimic group and the Minoxidil group increased rapidly, and the rising speed slowed down on the 21st day. The positive cell score in the Minoxidil group was the highest among all groups ( Fig.13 , Fig.17 C.).

[0078] LEF1: From the 14th day, it was expressed in the nuclei of the hair follicle bulb of each group. The positive cell fractions in the Mimic group and the Minoxidil group increased with time, reaching the highest expression level on the 21st day and decreasing on the 28th day. There was no significant difference in the expression of the two at the four time points, but they were all higher than the blank and inhibitor groups ( Fig.14 , Fig.17 D.)

[0079] C-myc and CyclinD1: Different treatment groups expressed C-myc and CyclinD1 in the nuclei of the outer root sheath cells and epidermal cells of the hair follicles. In the first 21 days of each group, the expression levels of C-myc and CyclinD1 increased with time, reaching a peak on the 21st day, and then decreased on the 28th day; on the 28th day, there was no statistically significant difference in the C-myc positive cell score between the Mimic group and the other groups, and the CyclinD1 positive cell score was higher than that of the blank control group and the Inhibitor group, which was equivalent to minoxidil. ( Fig.15 , Fig.16 , Fig.17 EF)

[0080] In summary, the present invention promotes hair follicle growth by administering drugs through skin microneedles; miR-221-3p achieves stability and targeting through 20-OMe phosphoramidite modification and cell membrane wrapping; miR-221-3p regulates the hair follicle growth cycle of AGA model mice; miR-221-3p regulates Wnt signal transduction to improve the hair growth phase of AGA model mice.

Claims

1. Use of miR-221-3p in the preparation of topical drugs for the treatment of androgenic alopecia.

2. The use according to claim 1, characterized in that: The medicine is a medicine for regulating the growth cycle of hair follicles.

3. The use according to claim 1, characterized in that: The medicine is a medicine for improving the hair growth phase.

4. A pharmaceutical composition for treating androgenic alopecia, characterized in that: It is a preparation prepared by cell membrane-encapsulated miR-221-3p or miR-221-3p modified with 20-OMe phosphoramidite.

5. The pharmaceutical composition for treating androgenic alopecia according to claim 4, characterized in that: The preparations are rolling needle, subcutaneous injection, and microneedle.

6. The pharmaceutical composition for treating androgenic alopecia according to claim 4, characterized in that: The cell membrane is derived from the skin precursor cell extract described in Patent No. ZL202010192592.

7.

7. The pharmaceutical composition for treating androgenic alopecia according to claim 6, characterized in that: The cell membrane extraction method comprises the following steps: After culturing human skin precursor cells to 80% confluence, the culture medium was poured out, washed with PBS, and the cell pellet was collected; Add membrane extract solution for lysis, shake at 4°C, and after the cells are broken, centrifuge at 700 rpm for 10 minutes to take the supernatant, and centrifuge at 12000 rpm for 50 minutes to collect the precipitate to obtain the cell membrane (CM).

8. A method for preparing the pharmaceutical composition for treating androgenic alopecia according to any one of claims 4 to 7, characterized in that: It is prepared by the following steps: a. Extract cell membrane and prepare suspension; b. preparing a suspension of miR-221-3p or miR-221-3p modified with 20-OMe phosphoramidite; c. The cell membrane suspension is mixed with the suspension of miR-221-3p-mimic to prepare liposomes, which are self-assembled into a cell membrane-wrapped structure, and then pharmaceutically acceptable excipients or auxiliary ingredients are added to prepare a commonly used external preparation.

9. The method for preparing the pharmaceutical composition for treating androgenic alopecia according to claim 8, characterized in that: The cell membrane suspension described in step a is prepared with sterile RNase-free-PBS to a concentration of 0.2 mg / ml; The concentration of the miR-221-3P solution in step b is 20uM; The volume ratio of cell membrane suspension to cell membrane suspension was 1:8.